Bibek Aryal, Surgeon-Scientist and Independent Researcher in Cancer Outcomes, shares insights on the emerging “Myokinib” framework:
“The ‘Myokinib‘ framework was born from a simple observation: we already have robust evidence that structured exercise profoundly impacts cancer outcomes, yet it remains outside our formal care pathways – relegated to lifestyle advice rather than treated as the therapeutic it is.
The science is not the barrier. Trials like CHALLENGE have confirmed survival benefit. What has been missing is a structural framework to prescribe it with the same rigor we apply to any systemic treatment.
By naming it – by calling it Myokinib – the goal is to give clinicians a formal entry point to operationalize exercise in oncology care, and to ensure it reaches patients in settings where modern biologics remain inaccessible.”
Title: The Myokinib monograph: operationalizing oncology’s highest-value systemic therapeutic
Author: Bibek Aryal
Read the Full Article.
Other articles featuring Bibek Aryal on OncoDaily.